Genome-wide CRISPR screen for essential cell growth mediators in mutant KRAS colorectal cancers

Cancer Research

Volumn 77, Issue 22, 2017, Pages 6330-6339

  Yau, Edwin H ^a,b,c,d   Kummetha, Indrasena Reddy ^a   Lichinchi, Gianluigi ^a   Tang, Rachel ^a   Zhang, Yunlin ^a   Rana, Tariq M ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOHEXOKINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; DNA HELICASE; FRUCTOKINASE; INO80 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE KINASE; PHOSPHOTRANSFERASE; PROTEIN P21; THIONICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; ENZYME METABOLISM; GENE IDENTIFICATION; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LETHAL MUTATION; LOSS OF FUNCTION MUTATION; MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA SEQUENCE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WILD TYPE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; COLORECTAL TUMOR; CRISPR CAS SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETICS; HCT 116 CELL LINE; MUTATION; PATHOLOGY; PROCEDURES; PROTEIN SUBUNIT; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CRISPR-CAS SYSTEMS; DNA HELICASES; FRUCTOKINASES; GENOME-WIDE ASSOCIATION STUDY; HCT116 CELLS; HUMANS; MUTATION; NIACINAMIDE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS P21(RAS); XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85033791261     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-2043     Document Type: Article

References (43)

1. Downward J. RAS synthetic lethal screens revisited: still seeking the elusive prize? Clin Cancer Res 2015;21:1802–9.
2. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014;25:272–81.
3. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.
4. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816–21.
5. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.
6. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 2016;34:184–91.
7. Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 2015;163:1515–26.
8. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014;11:783–4.
9. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84–7.
10. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science 2015;350:1096–101.
11. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 2015;160:1246–60.
12. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Jordan AD Jr, et al. Inhibitors of ketohexokinase: discovery of pyrimidinopyrimidines with specific substitution that complements the ATP-binding site. ACS Med Chem Lett 2011;2:538–43.
13. Zhou Y, Dang J, Chang KY, Yau E, Aza-Blanc P, Moscat J, et al. miR-1298 inhibits mutant KRAS-driven tumor growth by repressing FAK and LAMB3. Cancer Res 2016;76:5777–87.
14. Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol 2014;10:733.
15. Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang C-Z, Ben-David U, et al. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov 2016;6:914–29.
16. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656–70.
17. Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. NADþ kinase as a therapeutic target in cancer. Clin Cancer Res 2016;22:5189–95.
18. Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, et al. Suppression of cytosolic NADPH pool by thionicotinamide increases oxidative stress and synergizes with chemotherapy. Mol Pharmacol 2015;88:720–7.
19. Li X, Qian X, Lu Z. Fructokinase A acts as a protein kinase to promote nucleotide synthesis. Cell Cycle 2016;15:2689–90.
20. Li X, Qian X, Peng LX, Jiang Y, Hawke DH. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. 2016;18:561–71.
21. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci 2008;105:20380–5.
22. Kim S, Jho E-H. Merlin, a regulator of Hippo signaling, regulates Wnt/ b-catenin signaling. BMB Rep 2016;49:357–8.
23. Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, et al. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/b-catenin signaling in cancer. Oncotarget 2016;7:17991–8005.
24. Hikasa H, Sekido Y, Suzuki A. Merlin/NF2-Lin28B-let-7 is a tumor-suppressive pathway that is cell-density dependent and hippo independent. Cell Rep 2016;14:2950–61.
25. Martin TD, Chen X-W, Kaplan REW, Saltiel AR, Walker CL, Reiner DJ, et al. Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. Mol Cell 2014;53:209–20.
26. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2012;2:881–98.
27. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab 2016;23:517–28.
28. Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun 2016;7:10500.
29. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015;350:1391–6.
30. Liu H, Huang D, McArthur DL, Boros LG, Nissen N, Heaney AP. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 2010;70:6368–76.
31. Muto Y, Pomeranz Krummel D, Oubridge C, Hernandez H, Robinson CV, Neuhaus D, et al. The structure and biochemical properties of the human spliceosomal protein U1C. J Mol Biol 2004;341:185–98.
32. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000;275:24865–71.
33. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. J Biol Chem 2002;277:535–43.
34. Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003;63:4268–74.
35. Silvany RE, Eliazer S, Wolff NC, Ilaria RL. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000;19:4523–30.
36. van Eenennaam H, Lugtenberg D, Vogelzangs JH, van Venrooij WJ, Pruijn GJ. hPop5, a protein subunit of the human RNase MRP and RNase P endoribonucleases. J Biol Chem 2001;276:31635–41.
37. Terada Y, Yasuda Y. Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145. Mol Cell Biol 2006;26:8149–58.
38. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011;71:78–86.
39. Zhang S, Zhou B, Wang L, Li P, Bennett BD, Snyder R, et al. INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer. Oncogene 2017;36:1430–9.
40. Zhou B, Wang L, Zhang S, Bennett BD, He F, Zhang Y, et al. INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma. Genes Dev 2016;30:1440–53.
41. Segala G, Bennesch MA, Pandey DP, Hulo N, Picard D. Monoubiquitination of histone H2B blocks eviction of histone variant H2A.Z from inducible enhancers. Mol Cell 2016;64:334–46.
42. Yao W, King DA, Beckwith SL, Gowans GJ, Yen K, Zhou C, et al. The INO80 complex requires the Arp5-Ies6 subcomplex for chromatin remodeling and metabolic regulation. Mol Cell Biol 2016;36:979–91.
43. Xue Y, Van C, Pradhan SK, Su T, Gehrke J, Kuryan BG, et al. The Ino80 complex prevents invasion of euchromatin into silent chromatin. Genes Dev 2015;29:350–5.